英菲格拉替尼(Infigratinib)2025年正规购买渠道有哪些

Infigratinib is suitable for the treatment of previously treated unresectable locally advanced or metastatic cholangiocarcinoma that has been confirmed to have fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangements. This article mainly introduces the purchasing channels of this drug.

What are the regular purchase channels for Infigratinib in 2025?

As of 2025, Infigratinib has not yet received marketing approval from the China National Medical Products Administration (NMPA), and has not been included in the scope of medical insurance reimbursement.

Purchase overseas

Patients may consider purchasing in countries or regions that have been approved for marketing. It can be purchased from regular pharmacies in the United States, Canada and other countries with a prescription. When purchasing, you must confirm that the drug packaging is complete. The 100mg capsules should be white with a light orange cap and clearly marked.

Online purchase

Some online platforms can also purchase this medicine. When choosing, you need to confirm that the platform has business qualifications and can provide drug traceability information. For online purchases, you need to prepare valid prescriptions and other information. It is recommended to choose a formal and legal platform.

Infigratinib usage and dosage

Standardized medication can maintain the therapeutic effect to the greatest extent. Please strictly follow the following medication instructions.

Standard dosage regimen

The recommended dose is 125 mg once a day (1 tablet each of 100 mg + 25 mg), taken continuously for 21 days and then stopped for 7 days, and 28 days is a complete cycle. It must be taken on an empty stomach. It is recommended to fix the daily taking time. It is best to take it 1 hour before or 2 hours after a meal. Swallow capsules whole, do not chew or open capsules.

Adjustments under special circumstances

When adverse reactions of grade 2 or above occur, the dose needs to be gradually reduced, to 100mg/day for the first time, to 75mg/day for the second time, and to 50mg/day for the third time. It is recommended that the starting dose be adjusted to 100 mg/day for patients with mild liver and renal impairment, and 75 mg/day for patients with moderate liver impairment. All dosage adjustments should be made under physician supervision.

Management of drug interactions

Avoid coadministration with strong CYP3A inhibitors (such as ketoconazole) or inducers (such as rifampicin). When gastric acid suppressants must be used, proton pump inhibitors need to be completely avoided, H2 receptor antagonists should be used 2 hours before or 10 hours after infigratinib, and antacids should be taken 2 hours apart.

Special medication groups for Infigratinib

There are differences in medication for patients with different physiological conditions, and individualized medication management is required.

Women of childbearing age and pregnancy

Women of childbearing age must confirm that they are not pregnant before taking the drug, and must take effective contraceptive measures during treatment and within 1 month after stopping the drug. It is contraindicated during pregnancy as animal studies have shown that it may cause fetal malformation. Breastfeeding in lactating women should be suspended during treatment.

Elderly patients and patients with abnormal liver and renal function

Elderly patients over 65 years old usually do not need to adjust the dosage. For patients with mild renal impairment (eGFR 60-89ml/min) or mild liver impairment (Child-Pugh Class A), the recommended starting dose is 100 mg/day.

For patients with moderate hepatic impairment (Child-Pugh class B), 75 mg/day is recommended. Data on drug safety in patients with severe hepatic and renal impairment are limited and need to be evaluated with caution.

The safety and effectiveness of the drug have not been established for children and adolescents under 18 years of age, and its use is not recommended. Special circumstances require a decision by a specialist after assessing the risks and benefits.